MetaCap

HCW Biologics (HCWB) vs Redhill Biopharma (RDHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Redhill Biopharma is the larger company by market cap ($2.5 million vs $2.4 million), about 1.1 times the size. Redhill Biopharma converts more of its revenue into profit, with a net margin of -102.8% versus -14677.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCWB-51.98%RDHL-40.72%
+26%-15%-57%
Oct 7, 20261 yearNov 20, 2026
HCWB-53.18%RDHL-47.87%
+3%-27%-56%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCWB versus RDHL key metrics
MetricHCWBRDHL
Share price$0.7491$0.281
Market cap$2.35M$2.50M
1-day change+1.90%-13.08%
Forward P/E—9.37
EPS (TTM)$-9.09$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.23K$8.04M
Revenue growth (YoY)-97.89%+23.17%
Net income (latest FY)$-7.96M$-8.27M
Gross margin20.00%60.31%
Operating margin-24270.74%-181.69%
Net margin-14677.14%-102.80%
52-week high$23.94$1.60
52-week low$0.70$0.281
Distance from 52-week high-96.87%-82.44%
Analyst consensusbuy—
Avg. price target upside+6307.69%—
Average volume379.38K2.08M
Shares outstanding3.14M8.89M
Employees3513
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Redhill Biopharma is more profitable, keeping -102.8 cents of every revenue dollar as net income versus -14677.1 cents for HCW Biologics.
  • Redhill Biopharma grew revenue faster in its latest fiscal year (+23.17% vs -97.89%).

About HCW Biologics

HCWB stock →

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

About Redhill Biopharma

RDHL stock →

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

HCWB vs RDHL FAQ

Which is bigger, HCW Biologics or Redhill Biopharma?

Redhill Biopharma (RDHL) is larger, with a market capitalization of $2.50M compared with $2.35M for HCW Biologics (HCWB).

Are HCW Biologics and Redhill Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons